Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the National Cancer Institute Director's Consumer Liaison Group.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations should notify the Contact Person listed below in advance of the meeting.

Name of Committee: National Cancer Institute Director's Consumer Liaison Group.

Date: January 24, 2008.

Time: 1 p.m. to 3 p.m.

Agenda: 1. Approval of Minutes; 2. Reports from Dr. John E. Niederhuber, NCI Director; 3. Report from Shannon Bell, OAR Director; 4. Discussion of Recommendations at DCLG October inperson meetings; 5. Reports from DCLG members of NCI Committee Assignments; 6. Public Comment; 7. Action Items and Conclusion.

Place: National Institutes of Health, 61l6 Executive Bo ]]> http://thefederalregister.com/d.p/2007-12-20-07-6104 Thu, Dec 20 2007 11:00:00 GMT http://thefederalregister.com/d.p/2007-12-20-07-6083

Pursuant to section 10(d) of the Federal Advisory Committee Act, as aamended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. [[Page 72366]]

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel, ``Bcell P01 appplications''.

Date: January 10, 2008.

Time: 12 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge 6700, 6700B Rockledge Drive, Bethesda, MD 20817, (Telephone Conference Call). ]]> http://thefederalregister.com/d.p/2007-12-20-07-6083 Thu, Dec 20 2007 11:00:00 GMT http://thefederalregister.com/d.p/2007-12-20-07-6084

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel, ``Host Response to Pathogens''.

Date: January 10, 2008.

Time: 1 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge 6700, 6700B Rockledge Drive, Bethesda, MD 20817, (Telephone Conference Call).

Contact Pe ]]> http://thefederalregister.com/d.p/2007-12-20-07-6084 Thu, Dec 20 2007 11:00:00 GMT http://thefederalregister.com/d.p/2007-12-20-07-6082

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Dental and Craniofacial Research.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute of Dental & Craniofacial Research, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors, National Institute of Dental and Craniofacial Research.

Date: January 68, 2008.

Time: January 6, 2008, 5 p.m. to 9:30 p.m.

Agenda: To review and evaluate personal qualifications and ]]> http://thefederalregister.com/d.p/2007-12-20-07-6082 Thu, Dec 20 2007 11:00:00 GMT http://thefederalregister.com/d.p/2007-12-20-07-6080

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council for Nursing Research.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Nationa ]]> http://thefederalregister.com/d.p/2007-12-20-07-6080 Thu, Dec 20 2007 11:00:00 GMT http://thefederalregister.com/d.p/2007-12-20-07-6085

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council on Drug Abuse.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advis ]]> http://thefederalregister.com/d.p/2007-12-20-07-6085 Thu, Dec 20 2007 11:00:00 GMT http://thefederalregister.com/d.p/2007-12-20-07-6086

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. [[Page 72367]]

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Design and Synthesis of Treatment Agents for Drug Abuse.

Date: December 18, 2007.

Time: 10:20 a.m. to 1 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).
]]> http://thefederalregister.com/d.p/2007-12-20-07-6086 Thu, Dec 20 2007 11:00:00 GMT http://thefederalregister.com/d.p/2007-12-20-07-6087

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, MIDARP.

Date: January 10, 2008.

Time: 10 a.m. to 11 a.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: Nadine Rogers, PhD, Scientific Review Administra ]]> http://thefederalregister.com/d.p/2007-12-20-07-6087 Thu, Dec 20 2007 11:00:00 GMT http://thefederalregister.com/d.p/2007-12-20-07-6081

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Recombinant DNA Advisory Committee.

Date: January 14, 2008.

Time: 3 p.m. to 4 p.m.

Agenda: Recombinant DNA Advisory Committee teleconference will meet to discuss the followup of a Serious Adverse Event on a Human Gene Transfer Trial (OBA Protocol 0504705) Using an Adeno Associated Viral Vector: Analysis of Its Scientific and Safety Implications.

Place: National Institutes of Health, Building 31, 31 Center Drive, Sixth Floor, C Wing, Room 6, Bethesda, MD 20892, (Telephone Conference Ca ]]> http://thefederalregister.com/d.p/2007-12-20-07-6081 Thu, Dec 20 2007 11:00:00 GMT